Manipal Health Enterprises reported a 38.1% year-on-year revenue increase to ₹3,091 crore for the quarter ended June 30, 2026. The pan-India hospital chain delivered strong operational metrics as it absorbed capacity from its recent Sahyadri acquisition.

The company posted an EBITDA of ₹749 crore, reflecting a 26.4% year-on-year growth. Excluding a one-off gain of ₹15 crore recorded in the prior year period, adjusted EBITDA growth stood at 29.7%. Profit after tax (PAT) was reported at ₹243 crore. However, excluding ₹89 crore in post-tax interest on non-convertible debentures raised for the Sahyadri acquisition, adjusted PAT grew 30.9% year-on-year.

Operational Metrics

Patient volumes drove the top-line expansion. Inpatient volumes rose 38.8% year-on-year, while outpatient volumes increased by 26.0%. Occupancy rates improved by 290 basis points to 65.0%, indicating effective utilization of the expanded network. Average Revenue Per Occupied Bed (ARPOB), excluding the Sahyadri portfolio, grew 8.7% year-on-year to ₹77,200 per day, signaling improved revenue intensity across the existing legacy network.

What the Numbers Show

Reported PAT declined 4.2% year-on-year to ₹243 crore, contrasting sharply with the 38.1% revenue growth. This divergence is attributable to the ₹89 crore post-tax interest expense on debt raised for the Sahyadri acquisition. When this financing cost is excluded, underlying profitability grew 30.9%, demonstrating that the core operational performance outpaced the drag from acquisition-related leverage.

Sahyadri Integration

Sahyadri Hospitals contributed significantly to the quarter's performance, recording 12.8% revenue growth and 18.7% EBITDA growth year-on-year based on erstwhile management reporting. The integration has progressed across clinical and operational functions, with centralized procurement pricing and co-branding initiatives already implemented. Sahyadri's ARPOB improved by 14.7% year-on-year to ₹44,800 per day.

Specialty Mix

High-acuity specialties continued to drive momentum within the network. Gross inpatient revenue from CONGO-R specialties (Cardiac, Oncology, Neuro, Gastro, Ortho, Renal) grew 45% year-on-year. Oncology and Orthopedics were key contributors, with inpatient revenue growth of 62% and 49% respectively. The specialty mix for these high-value procedures increased to 65.4% of total gross inpatient revenue.

Promoter group entities of manipal health enterprises limited have pledged 6,31,70,773 equity shares to secure non-convertible debentures (NCDs) issued by associated private limited companies. This disclosure, made under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reveals that Vistra ITCL (India) Limited has been appointed as the common security trustee for these transactions. The pledge was created on August 5, 2026, shortly after the company’s listing on August 5, 2026, impacting approximately 4.80% of the total share capital and 4.74% on a fully diluted basis.

The encumbrance secures three separate tranches of unlisted, secured NCDs totaling INR 9,420 crore. These include INR 6,500 crore issued by Claypond Capital Partners Private Limited, INR 2,305 crore issued by Manipal Healthcare Private Limited (which has amalgamated into MEMG India), and INR 615 crore issued by Manipal Education and Medical Group India Private Limited. Vistra ITCL (India) Limited acts as the debenture trustee for each facility and as the common security trustee for the benefit of all respective debenture holders.

Share Pledge Details

The pledge is structured across two promoter group entities: Manipal Education and Medical Group India Private Limited (MEMG India) and MEMGIPL. The specific share counts and percentage holdings are detailed below.

In addition to the direct pledge, a larger block of shares remains encumbered through covenants. A total of 36,90,38,332 shares, representing 28.06% of the total share capital and 27.70% on a fully diluted basis, are subject to encumbrances via covenants agreed upon by MEMG India, MEMGIPL, and promoter Ranjan Pai. These covenants are part of the broader security structure supporting the NCD facilities.

Regulatory Framework and Trust Deeds

The security arrangements are governed by multiple amended trust deeds. The Claypond Capital Partners facility is secured under a debenture trust deed originally dated December 3, 2025, with subsequent amendments on January 21, 2026, and July 8, 2026. The Manipal Healthcare Private Limited facility relies on a trust deed originally dated July 10, 2023, which has been amended four times, most recently on August 3, 2026. The MEMG India facility is governed by a trust deed dated November 3, 2023.

The common security trustee agreement, initially dated July 10, 2023, was further amended and restated on April 4, 2024, January 21, 2026, and July 8, 2026. This agreement consolidates the security interests for the benefit of all debenture holders across the three NCD issuances. Personal guarantees provided by Ranjan Pai also form part of the security package for these debt instruments.

What the Numbers Show

The concentration of encumbrances highlights a significant linkage between the listed entity’s equity and the debt obligations of its promoter group. While only 4.80% of shares are directly pledged, the additional 23.26% of shares subject to covenants indicates that nearly 28% of the company’s voting power is tied to the repayment security of off-balance-sheet debt held by related private entities. This structure suggests that the financial health of the promoter group’s debt obligations is directly supported by the equity value of Manipal Health Enterprises Limited.